Skip to main content

Find Clinical Trials

Home
Conditions
HER2-positive Breast Cancer

Clinical trial condition

HER2-positive Breast Cancer

Explore clinical trials studying HER2-positive Breast Cancer. Study availability and eligibility vary by location and protocol.

202 public trials 83 recruiting studies

Refine in advanced search Browse all conditions

HER2-positive Breast Cancer trial results

Recruiting

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

NCT05306041

Conditions: HER2-positive Breast Cancer
Locations: KEM Kliniken Essen-Mitte Essen, North Rhine-Westphalia, Germany

Hämatologie-Onkologie im Zentrum MVZ GmbH Augsburg, Germany

DBZ Onkologie Berlin, Germany

Praxisklinik Krebsheilkunde für Frauen Berlin, Germany

View all 29 locations

View Trial Details

Recruiting

Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

NCT05388149

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +5 more
Locations: University Health Network: Princess Margaret Cancer Centre Toronto, Ontario, Canada

View Trial Details

Recruiting

Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC

NCT06754059

Conditions: HER2-positive Breast Cancer
Locations: Fujian Union Medical College Hospital Fuzhou, Fujian, China

View Trial Details

Recruiting

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

NCT06276868

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +10 more
Locations: Henan cacer hospital Henan, China

View Trial Details

Recruiting

Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer

NCT06722612

Conditions: HER2-positive Breast Cancer
Locations: Peking University People's Hospital Beijing, Beijing Municipality, China

View Trial Details

Recruiting

Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients

NCT06722599

Conditions: HER2-positive Breast Cancer
Locations: Peking University People's Hospital Beijing, Beijing Municipality, China

View Trial Details

Recruiting

Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy

NCT06711068

Conditions: HER2-positive Breast Cancer
Locations: Peking University People's Hospital Beijing, Beijing Municipality, China

View Trial Details

Recruiting

Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer

NCT06711055

Conditions: HER2-positive Breast Cancer
Locations: Peking University People's Hospital Beijing, Beijing Municipality, China

View Trial Details

Recruiting

De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients

NCT06700369

Conditions: HER2-positive Breast Cancer
Locations: Peking University People's Hospital Beijing, Beijing Municipality, China

View Trial Details

Recruiting

Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer

NCT06693024

Conditions: HER2-positive Breast Cancer
Locations: Peking University People's Hospital Beijing, Beijing Municipality, China

View Trial Details